Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
3
×
life sciences
3
×
national blog main
boston
deals
national top stories
new york blog main
san francisco blog main
san francisco top stories
startups
alphabet
azacitidine
beta-thalassemia
broad institute of harvard and mit
brook byers
cancer
charles chu
clinical trials
codiak biosciences
crispr
crispr cas14
cutaneous t-cell lymphoma
dacogen
decheng capital
decitabine
diagnostic
dna
epigenetics
epizyme
exosome
farydak
flagship pioneering
fulcrum therapeutics
google
infectious disease
insulated genomic domains
investing
jazz pharmaceuticals
What
based
3
×
biosciences
medicines
new
tiny
aims
approach
available
begin
big
bio
biotech
bio’s
brings
bubbles
called
cas
cells
cheaper
class
clinical
codiak
crispr
debuts
develop
developing
diagnostics
drugs
epigenetic
epigenetics
exosome
exosomes
expects
faster
field
flagship’s
formed
fund
ipo
mammoth
Language
unset
3
×
Current search:
based
×
" life sciences "
×
unset
×
" boston top stories "
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further